Paraoxonase 1 and homocysteine metabolism

Amino Acids

Volumn 43, Issue 4, 2012, Pages 1405-1417

  Perła Kaján, Joanna ^a   Jakubowski, Hieronim ^a,b,c  

^a POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Atherosclerosis; Homocysteine; N homocysteinylation; Paraoxonase 1; Thiolactonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ESTERASE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONASE; HOMOCYSTEINE THIOLACTONE; LIPOPROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROLYSIS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LIPOPROTEIN METABOLISM; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS;

ALZHEIMER DISEASE; ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MICE; OXIDATIVE STRESS; STROKE;

MUS;

EID: 84867579100     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1321-z     Document Type: Review

References (132)

1. Adkins S, Gan KN et al (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective Aor B allozymes. Am J Hum Genet 52(3):598-608
2. Amine K, Atouk Aet al (2011) Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients. Ann Biol Clin (Paris) 69(6):671-677
3. Anderson J, Muhlestein J et al (2000) Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102(11):1227-1232
4. Angayarkanni N, Barathi S et al (2008) Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Eye (Lond) 22(7):969-974
5. Atamer A, Kocyigit Y et al (2008) Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol 21(6):924-930
6. Ates O, Azizi S et al (2009) Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med 217(1):17-22
7. Aviram M, Billecke S et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617-1624
8. Aydin M, Gokkusu C et al (2009) Association of genetic variants in Methylenetetrahydrofolate Reductase and Paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem 325(1-2):199-208
9. Barathi S, Angayarkanni N et al (2010) Homocysteinethiolactone and paraoxonase: novel markers of diabetic retinopathy. Diabetes Care 33(9):2031-2037
10. Bayrak A, Bayrak T et al (2011) Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis. J Atheroscler Thromb 19(4):376-384
11. Bayrak T, Bayrak Aet al (2010) Purification and kinetic properties of rabbit liver paraoxonase 1. J Chromatogr B Analyt Technol Biomed Life Sci 878(21):1791-1795
12. Bayrak A, Bayrak T et al (2011) Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes. J Chromatogr B Analyt Technol Biomed Life Sci 879(1):49-55
13. Beltowski J, Wojcicka G et al (2010) Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. J Endocrinol 204(2):191-198
14. Ben-David M, Elias M et al (2012) Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol 418(3-4):181-196
15. Bhattacharyya T, Nicholls SJ et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265-1276
16. Blatter MC, James RW et al (1993) Identification of Adistinct human high-density lipoprotein subspecies defined by Alipoprotein-Associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211(3):871-879
17. Borowczyk K, Shih DM et al (2012a) Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for Aprotective role of paraoxonase 1. J Alzheimers Dis 30(2):225-231
18. Borowczyk K, Tisończyk J et al (2012b) Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase. Amino Acids. doi: 10.1007/s00726-011-1207-5
19. Bouman HJ, Schömig E et al (2011) Paraoxonase-1 is Amajor determinant of clopidogrel efficacy. Nat Med 17(1):110-116
20. Brophy VH, Jarvik GP et al (2000) Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10(5):453-460
21. Camps J, Joven J et al (2011) Paraoxonase-1 and clopidogrel efficacy. Nat Med 17(9):1041-1042
22. Can Demirdöǧen B, Türkanoǧlu Aet al (2008) Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 41(1-2):1-9
23. Cao H, Girard-Globa Aet al (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q- > R genetic polymorphism. J Lipid Res 40(1):133-139
24. Chang HH, Lin DP et al (2011) Intravitreal homocysteine-thiolactone injection leads to the degeneration of multiple retinal cells, including photoreceptors. Mol Vis 17:1946-1956
25. Chwatko G, Jakubowski H (2005a) The determination of homocysteine- thiolactone in human plasma. Anal Biochem 337(2):271-277
26. Chwatko G, Jakubowski H (2005b) Urinary excretion of homocysteine- thiolactone in humans. Clin Chem 51(2):408-415
27. Chwatko G, Boers GHJ et al (2007) Mutations in methylenetetrahydrofolate reductase or cystathionine beta-syntase gene, or Ahigh-methionine diet, increase homocysteine thiolactone levels in humans and mice. Faseb J 21(8):1707-1713
28. Coombes RH, Crow JA et al (2011) Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet Genomics 21(12):867-875
29. Costa LG, Vitalone Aet al (2005) Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69(4):541-550
30. Costa LG, Giordano G et al (2011) Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 81(3):337-344
31. Dansette PM, Rosi J et al (2011) Paraoxonase-1 and clopidogrel efficacy. Nat Med 17(9):1040-1041
32. Dansette PM, Rosi J et al (2012) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of Aminor thiol metabolite isomer. Chem Res Toxicol 25(2):348-356
33. Davies HG, Richter RJ et al (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14(3):334-336
34. Demirdöǧen BC, Demirkaya S et al (2009) Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population. Cell Biochem Funct 27(8):558-567
35. Domagala TB, Lacinski M et al (2006) The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol 52(5):4-10
36. Draganov DI, Teiber JF et al (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46(6):1239-1247
37. Dudman NP, Hicks C et al (1991) Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 11(3):663-670
38. Dunet V, Ruiz J et al (2011) Effects of paraoxonase activity and gene polymorphism on coronary vasomotion. EJNMMI Res 1(1):27
39. Fan AZ, Yesupriya Aet al (2010) Gene polymorphisms in association with emerging cardiovascular risk markers in adult women. BMC Med Genet 11:6
40. Ferretti G, Bacchetti T et al (2003) Effect of homocysteinylation on human high-density lipoproteins: Acorrelation with paraoxonase activity. Metabolism 52(2):146-151
41. Ferretti G, Bacchetti T et al (2010) Effect of homocysteinylation on high density lipoprotein physico-chemical properties. Chem Phys Lipids 163(2):228-235
42. Furlong CE, Holland N et al (2006) PON1 status of farm worker mothers and children as Apredictor of organophosphate sensitivity. Pharmacogenet Genomics 16(3):183-190
43. Gan KN, Smolen Aet al (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19(1):100-106
44. Garin MC, James RW et al (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. Apossible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99(1):62-66
45. Ghorbanihaghjo A, Javadzadeh Aet al (2008) Lipoprotein(a), homocysteine, and retinal arteriosclerosis. Mol Vis 14:1692-1697
46. Giusti B, Saracini C et al (2008) Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm. J Med Genet 45(11):721-730
47. Giusti B, Saracini C et al (2010) Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. Thromb Haemost 104(2):231-242
48. Glowacki R, Jakubowski H (2004) Cross-talk between Cys(34) and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 279(12):10864-10871
49. Gong M, Garige M et al (2009) Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 379(4):1001-1004
50. Guéant-Rodriguez RM, Spada R et al (2011) Homocysteine is Adeterminant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis 214(2):480-485
51. Gugliucci A, Kinugasa E et al (2011) Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 49(1):61-67
52. Gupta N, Binukumar BK et al (2011a) Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in ANorth-West Indian population. Gene 487(1):88-95
53. Gupta N, Singh S et al (2011b) Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS ONE 6(5):e17805
54. Harel M, Aharoni Aet al (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-Atherosclerotic enzymes. Nat Struct Mol Biol 11(5):412-419
55. Hassett C, Richter RJ et al (1991) Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30(42):10141-10149
56. Holven KB, Aukrust P et al (2008) The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J Nutr 138(11):2070-2075
57. Humbert R, Adler DA et al (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3(1):73-76
58. Ikeda Y, Suehiro T et al (2007) Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 67(6):358-365
59. Isbilen E, Yilmaz H et al (2009) Association of paraoxonase 55 and 192 gene polymorphisms on serum homocysteine concentrations in preeclampsia. Folia Biol (Praha) 55(2):35-40
60. Ishimine N, Usami Y et al (2010) Identification of N-homocysteinylated apolipoprotein AI in normal human serum. Ann Clin Biochem 47(Pt 5):453-459
61. Itahara T, Suehiro T et al (2000) Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 7(3):152-158
62. Jakubowski H (1997) Metabolism of homocysteine thiolactone in human cell culturespossible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 272(3):1935-1942
63. Jakubowski H (1999) Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. Faseb J 13(15):2277-2283
64. Jakubowski H (2000a) Calcium-dependent human serum homocysteine thiolactone hydrolasea protective mechanism against protein s- homocysteinylation. J Biol Chem 275(6):3957-3962
65. Jakubowski H (2000b) Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 130(2):377S-381S
66. Jakubowski, H. (2008). Paraoxonase 1 (PON1), Ajunction between the metabolism of homocysteine and lipids. Paraoxonases Their Role Dis Dev Xenobiotic Metabol 6:87-102
67. Jakubowski H (2010) The Role of Paraoxonase 1 in the Detoxification of Homocysteine Thiolactone. Paraoxonases Inflamm Infection Toxicol 660:113-127
68. Jakubowski H (2011) Quality control in tRNA chargingediting of homocysteine. Acta Biochim Pol 58(2):149-163
69. Jakubowski H (2012) Quality control in tRNA charging. Wiley Interdiscip Rev RNA 3(3):295-310
70. Jakubowski H, Zhang L et al (2000) Homocysteine thiolactone and protein homocysteinylation in human endothelial cellsimplications for atherosclerosis. Circ Res 87(1):45-51
71. Jakubowski H, Ambrosius WT et al (2001) Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 491(1-2):35-39
72. Jakubowski H, Boers GHJ et al (2008) Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. Faseb J 22(12):4071-4076
73. Jakubowski H, Perla-Kajan J et al (2009) Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. Faseb J 23(6):1721-1727
74. Javadzadeh A, Ghorbanihaghjo Aet al (2010) Plasma oxidized LDL and thiol-containing molecules in patients with exudative age-related macular degeneration. Mol Vis 16:2578-2584
75. Javadzadeh A, Ghorbanihaghjo Aet al (2012) Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Retina 32(4):658-666
76. Kelso GJ, Stuart WD et al (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33(3):832-839
77. Khersonsky O, Tawfik DS (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44(16):6371-6382
78. Kimak E, Hałabiś M et al (2011) Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients. J Zhejiang Univ Sci B 12(5):365-371
79. Kosaka T, Yamaguchi M et al (2005) Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using Acommercially available assay. Clin Chim Acta 359(1-2):156-162
80. Koubaa N, Nakbi Aet al (2009) Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 42(9):771-776
81. Kreutz RP, Nystrom P et al (2012) Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol 4:13-20
82. Lacinski M, Skorupski W et al (2004) Determinants of homocysteine- thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand) 50(8):885-893
83. Lacinski M, Skorupski W et al (2004) Determinants of homocysteine- thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol 50(8):885-893
84. Lakshman R, Garige M et al (2009) Is alcohol beneficial or harmful for cardioprotection? Genes Nutr 5(2):111-120
85. Leviev I, Negro F et al (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17(11):2935-2939
86. Leviev I, Deakin S et al (2001) Decreased stability of the M54 isoform of paraoxonase as Acontributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42(4):528-535
87. Lewis JP, Shuldiner AR (2012) Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction? Circ Cardiovasc Genet 5(2):153-155
88. Liao D, Tan H et al (2006) Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99(6):598-606
89. Liu G, Nellaiappan K et al (1997) Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 272(51):32370-32377
90. Mackness MI, Arrol S et al (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104(1-2):129-135
91. Mackness B, Mackness MI et al (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139(2):341-349
92. Mackness B, Davies GK et al (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21(9):1451-1457
93. Man BL, Baum L et al (2010) Genetic polymorphisms of Chinese patients with ischemic stroke and concurrent stenoses of extracranial and intracranial vessels. J Clin Neurosci 17(10):1244-1247
94. Marathe GK, Zimmerman GA et al (2003) Platelet-Activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 278(6):3937-3947
95. Marsillach J, Mackness B et al (2008) Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 45(2):146-157
96. Mikael LG, Genest J et al (2006) Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 98(4):564-571
97. Mu X, Yu N et al (2012) Evaluation of Anew substrate for measurement of serum PON arylesterase activity. Talanta 88:711-716
98. Oda MN, Bielicki JK et al (2002) Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290(3):921-927
99. Ohmori T, Yano Y et al (2012) Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb Res 129(4):e36-e40
100. Perla J, Undas Aet al (2004) Purification of antibodies against N-homocysteinylated proteins by affinity chromatography on N omega-homocysteinyl-Aminohexyl-Agarose. J Chromatograph B-Anal Technol Biomed Life Sci 807(2):257-261
101. Perla-Kaján J, Jakubowski H (2010) Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 24(3):931-936
102. Perla-Kajan J, Stanger O et al (2008) Immunohistochernical detection of N-homocysteinylated proteins in humans and mice. Biomed Pharmacother 62(7):473-479
103. Perna AF, Ingrosso D et al (2004) Homocysteine metabolism in renal failure. Curr Opin Clin Nutr Metab Care 7(1):53-57
104. Perna AF, Satta E et al (2006) Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 69(5):869-876
105. Qujeq D, Omran TS et al (2001) Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 34(2):97-101
106. Rajković MG, Rumora L et al (2010) Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clin Biochem 43(18):1375-1380
107. Reddy ST, Wadleigh DJ et al (2001) Human paraoxonase-3 is an HDL-Associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21(4):542-547
108. Richter RJ, Jarvik GP et al (2010) Paraoxonase 1 status as Arisk factor for disease or exposure. Adv Exp Med Biol 660:29-35
109. Rozenberg O, Shih DM et al (2005) Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181(1):9-18
110. Rozenberg O, Shiner M et al (2008) Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 44(11):1951-1959
111. Sauls DL, Lockhart E et al (2006) Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: Apotential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 45(8):2480-2487
112. She ZG, Zheng W et al (2009) Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res 104(10):1160-1168
113. Shih DM, Gu L et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284-287
114. Shih DM, Xia YR et al (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275(23):17527-17535
115. Shih DM, Xia YR et al (2007) Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 100(8):1200-1207
116. Shin BS, Oh SY et al (2008) The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand 117(4):237-243
117. Sodi A, Giambene B et al (2008) Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion. Eur J Ophthalmol 18(2):233-238
118. Suehiro T, Ikeda Y et al (2002) Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 9(3):133-138
119. Suszynska J, Tisonczyk J et al (2010) Reduced homocysteine-thiolactonase activity in Alzheimer's disease. J Alzheimers Dis 19(4):1177-1183
120. Sztanek F, Seres I et al (2012) Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. Anovel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant. doi: 10.1093/ndt/gfr753
121. Teiber JF, Draganov DI et al (2004) Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 45(12):2260-2268
122. Türkeli H, CaycI T et al (2010) Paraoxonase-1 activity determination via paraoxon substrate yields no significant difference in mild hyperhomocysteinemia. Int J Cardiol 145(1):42-43
123. Tward A, Xia YR et al (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106(4):484-490
124. Undas A, Perla J et al (2004) Autoantibodies against N-homocysteinylated proteins in humansImplications for atherosclerosis. Stroke 35(6):1299-1304
125. Undas A, Stepien E et al (2006) Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost 96(3):342-347
126. Varga E, Seres I et al (2009) Serum cystatin C is Adeterminant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis Markers 26(3):141-148
127. Vos E (2008) Homocysteine levels, paraoxonase 1 (PON1) activity, and cardiovascular risk. JAMA 300(2):168-169 (author reply 169)
128. Wehr H, Bednarska-Makaruk M et al (2009) Paraoxonase activity and dementia. J Neurol Sci 283(1-2):107-108
129. Weijun G, Juming L et al (2008) Effects of plasma homocysteine levels on serum HTase/PON activity in patients with type 2 diabetes. Adv Ther 25(9):884-893
130. Zafiropoulos A, Linardakis M et al (2010) Paraoxonase 1 R/Q alleles are associated with differential accumulation of saturated versus 20:5n3 fatty acid in human adipose tissue. J Lipid Res 51(7):1991-2000
131. Zengi O, Karakas Aet al (2011) Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease. Clin Chem Lab Med 50(3):529-534
132. Zhao Y, Ma Y et al (2012) Association between PON1 activity and coronary heart disease risk: Ameta-Analysis based on 43 studies. Mol Genet Metab 105(1):141-148